Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature

Berger, Garrett K.; Gee, Kevin; Votruba, Cassandra; McBride, Ali; Anwer, Faiz

doi:10.1016/j.critrevonc.2017.02.021

Cited by 13 publications

(14 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD30 is a defining marker for embryonal carcinoma . Brentuximab‐vedotin conjugates chimeric anti‐CD30 antibody to an antitubulin synthetic analog monomethyl auristatin E .…”

Section: Future Directionsmentioning

confidence: 99%

“…89 CD30 is a defining marker for embryonal carcinoma. 92,93 Brentuximab-vedotin conjugates chimeric anti-CD30 antibody to an antitubulin synthetic analog monomethyl auristatin E. 94 Its clinical efficacy is well proven in patients with recurrent CD30-positive tumors such as anaplastic large cell lymphoma and Hodgkin disease, and showed favorable responses among patients with heavily pretreated refractory testicular GCT. 95,96 However, no studies have evaluated its ability to cross the blood-brain barrier, as the utilization of brentuximab-vedotin in intracranial embryonal carcinoma is limited to only one case report.…”

Section: Of 63 Patients (22%) With Relapsed Cns-nggct Documentedmentioning

confidence: 99%

See 1 more Smart Citation

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

Arja

Bouffet

Finlay

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Multimodal strategies have significantly improved the outcomes for patients with central nervous system nongerminomatous germ cell tumors. Two large cooperative group studies have recently reported much improved outcomes compared with historical series. However, a substantial proportion of patients still attain inadequate responses to initial chemotherapy prior to irradiation, with adverse impact upon survival; optimal induction chemotherapy regimens and radiotherapy strategies are as yet unidentified. Outcomes for patients with relapsed disease remain poor. There is an obvious need to incorporate molecular studies within prospective clinical trials that will likely lead to the incorporation of targeted, more effective future treatment strategies.

show abstract

“…CD30 is a defining marker for embryonal carcinoma . Brentuximab‐vedotin conjugates chimeric anti‐CD30 antibody to an antitubulin synthetic analog monomethyl auristatin E .…”

Section: Future Directionsmentioning

confidence: 99%

Section: Of 63 Patients (22%) With Relapsed Cns-nggct Documentedmentioning

confidence: 99%

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

Arja

Bouffet

Finlay

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…indeed, both occur in the immune-rich lymphoid tissues and are easily accessible to antibody-and cellbased immunotherapy (5). Moreover, CD30, a cell-membrane protein belonging to the tumor-necrosisfactor receptor superfamily 8, can be found on the cell-surface of both HL and selected NHL including ALCL, DLBCL, primary mediastinal B-cell lymphoma(6), peripheral T-cell lymphoma (7), and adult T-cell leukemia/lymphoma (8), as well as in rare solid tumors (9), including embryonal carcinomas (10) and seminomas (11). Its restricted expression on a subset of normal, activated T and B cells (12,13) renders CD30 an excellent candidate for immune-based therapies, with a low risk for off-tumor, ontarget toxicity.…”

mentioning

confidence: 99%

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Besides cHL also other types of cancer such as anaplastic large cell lymphoma (ALCL), cutaneous CD30-positive lymphoproliferative disorders, lymphomatoid papulomatosis, diffuse large B cell lymphoma or adult T cell leukemia can be CD30 positive [ 6 , 21 ]. Beyond that, also solid tumors especially mesothelioma and germ cell tumors can express CD30 [ 32 ]. The data we present here for the oncolytic activity of VSV-CD30 warrant further testing of this virus not only for applications in cHL, but also in these other CD30-positive disorders.…”

Section: Discussionmentioning

confidence: 99%

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

et al. 2018

View full text Add to dashboard Cite

Classical Hodgkin lymphoma (cHL) is a hematopoietic malignancy with a characteristic cellular composition. The tumor mass is made up of infiltrated lymphocytes and other cells of hematologic origin but only very few neoplastic cells that are mainly identified by the diagnostic marker CD30. While most patients with early stage cHL can be cured by standard therapy, treatment options for relapsed or refractory cHL are still not sufficient, although immunotherapy-based approaches for the treatment of cHL patients have gained ground in the last decade. Here, we suggest a novel therapeutic concept based on oncolytic viruses selectively destroying the CD30+-positive cHL tumor cells. Relying on a recently described CD30-specific scFv we have generated CD30-targeted measles virus (MV-CD30) and vesicular stomatitis virus (VSV-CD30). For VSV-CD30 the VSV glycoprotein G reading frame was replaced by those of the CD30-targeted MV glycoproteins. Both viruses were found to be highly selective for CD30-positive cells as demonstrated by infection of co-cultures of target and non-target cells as well as through blocking infection by soluble CD30. Notably, VSV-CD30 yielded much higher titers than MV-CD30 and resulted in a more rapid and efficient killing of cultivated cHL-derived cell lines. Mouse tumor models revealed that intratumorally, as well as systemically injected VSV-CD30, infected cHL xenografts and significantly slowed down tumor growth resulting in a substantially prolonged survival of tumor-bearing mice. Taken together, the data support further preclinical testing of VSV-CD30 as novel therapeutic agent for the treatment of cHL and other CD30+-positive malignancies.

show abstract

Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature

Cited by 13 publications

References 102 publications

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells

CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma

Contact Info

Product

Resources

About